Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines, and its news flow reflects this emphasis on cell and gene-based therapies. Company press releases and updates describe progress across its hypoimmune platform for allogeneic cell therapies and its fusogen platform for in vivo delivery of genetic payloads.
Investors following SANA news can read about clinical and preclinical milestones in type 1 diabetes, B-cell cancers, and B-cell–mediated autoimmune diseases. Sana has reported investigator-sponsored clinical data for UP421, a primary human pancreatic islet cell therapy engineered with hypoimmune technology, including results showing survival and function of transplanted beta cells without immunosuppression. News items also cover development of SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy, and in vivo CAR T candidates such as SG299 and SG293 built on the fusogen platform.
In addition to scientific and clinical updates, Sana’s news includes quarterly financial results, portfolio prioritization decisions, and capital-raising activities through public offerings and at-the-market equity programs. The company also issues announcements about participation in healthcare and investor conferences, where management provides business overviews and program updates.
This news page aggregates these disclosures so readers can monitor developments in Sana’s engineered cell programs, regulatory interactions, scientific publications, and financing events associated with the SANA stock. For investors and observers of the biotechnology sector, the SANA news stream offers insight into how the company is advancing its platforms and concentrating resources on type 1 diabetes and in vivo CAR T approaches.
Sana Biotechnology, Inc. (NASDAQ: SANA) reported a strong cash position of $746.9 million as of December 31, 2021, up from $412.0 million in 2020, driven by a successful IPO. The company is advancing its pipeline, anticipating two IND applications in 2022 for its CAR T programs, SC291 and SG295. Additionally, Sana made significant progress in research and development, including partnerships for stem cells and gene editing. However, the net loss for 2021 was $355.9 million, or $2.14 per share, indicating ongoing financial challenges as they scale operations and clinical trials.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference, scheduled for March 16, 2022, at 6:20 a.m. PT. The event will feature a presentation by CEO Steve Harr, providing a business overview and updates. The webcast can be accessed on the company's Investor Relations page, with a replay available for 30 days post-conference. Sana is focused on developing engineered cell therapies aimed at changing disease treatment.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced preclinical data from its hypoimmune T cell program, set to be presented at the 2022 AACR Annual Meeting from April 8-13 in New Orleans. The hypoimmune platform allows for allogeneic cell transplants without immunosuppression, demonstrating CAR T cells that evade immune response while maintaining anti-tumor efficacy. Sana plans to file investigational new drug applications for its CD19-expressing CAR T cell therapies, starting with SC291 in 2022 and SC276 in 2023.
Cellarity has announced key appointments to its executive team, enhancing its expertise in drug development. Laurens Kruidenier, Ph.D., joins as Chief Scientific Officer to lead drug platform evolution, while Anna O’Driscoll becomes Chief People Officer to drive talent development. Parul Doshi is appointed Senior VP, Head of Data and Software Engineering to bolster data infrastructure. These changes underscore Cellarity's commitment to advancing its drug creation process, particularly its unique approach that examines cellular changes underlying diseases, applicable across multiple therapeutic areas.
Sana Biotechnology (NASDAQ: SANA) has secured an exclusive worldwide license from the National Cancer Institute for the CD22 chimeric antigen receptor (CAR) technology. This agreement focuses on enhancing engineered T cell therapies for B cell malignancies, particularly addressing relapse challenges associated with current CD19-directed CAR therapies. With promising clinical data supporting the efficacy of CD22 CAR, Sana aims to improve outcomes for patients suffering from B cell malignancies, including non-Hodgkin lymphoma and acute lymphoblastic leukemia. Financial terms include upfront payments, milestone payments, and royalties on sales.
Sana Biotechnology has entered an agreement with IASO Biotherapeutics and Innovent Biologics to obtain non-exclusive commercial rights to a clinically validated BCMA CAR construct. This construct, part of an autologous CAR T cell therapy, has shown promising results for treating relapsed/refractory multiple myeloma, with a 94.9% overall response rate reported in clinical trials. The deal includes an upfront payment and potential milestone payments totaling up to $204 million.
Sana Biotechnology, Inc. (NASDAQ: SANA) will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 10:30 a.m. PT. The presentation, led by President and CEO Steve Harr, will provide a business overview and update. Interested investors can access the webcast on Sana's Investor Relations webpage, where a replay will be available for 30 days post-conference. Sana focuses on developing engineered cell therapies to treat diseases, aiming to repair genes and replace damaged cells.
Sana Biotechnology (NASDAQ: SANA) presented advancements at the 63rd ASH Annual Meeting. Notable highlights include data on hypoimmune CAR T cells that evade immune response in murine models and the use of fusosome technology for T cell delivery. Key presentations showed the effectiveness of hypoimmune CAR T cells against leukemia, and the capability of fusosomes to transduce T helper cells into CAR T cells. The company aims to file INDs for clinical trials in the upcoming year, signaling progression in their CAR T cell programs.
Generate Biomedicines has raised $370 million in a Series B financing to enhance its machine learning-powered Generative Biology platform, aimed at drug development across various protein modalities. This funding will facilitate technology evolution, organizational scaling from 80 to 500 employees, and the establishment of new facilities for computational biology and data generation. The company plans to advance several preclinical programs by year-end 2023, showcasing its pioneering efforts in programmable biotherapeutics.
Sana Biotechnology reported a net loss of $83.3 million for Q3 2021, translating to $0.46 per share, significantly higher than the $51.5 million loss ($3.76 per share) in Q3 2020. The company secured a cash position of $866.1 million, bolstered by $626.4 million from its IPO earlier in the year. Research and development expenses rose to $53.2 million, driven by increased personnel and operational costs. A notable development includes a license agreement with Beam for CRISPR technology, aimed at enhancing Sana's engineered cell therapy pipeline.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
